Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant

JK Edwards, JB Bossaer, PO Lewis… - Journal of Oncology …, 2020 - journals.sagepub.com
Background Peripheral neuropathy is a common treatment-related adverse effect associated
with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside …
被引用次数：13 相关文章

Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant

JK Edwards, JB Bossaer… - Journal of oncology …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Peripheral neuropathy is a common treatment-related adverse effect associated
with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside …

Peripheral Neuropathy in Non-Hodgkin's Lymphoma Patients Receiving Vincristine with and Without Aprepitant/Fosaprepitant

JK Edwards, JB Bossaer, PO Lewis… - Journal of Oncolology …, 2020 - dc.etsu.edu
Background: Peripheral neuropathy is a common treatment-related adverse effect
associated with vincristine. Vincristine is a major CYP3A4 substrate and is often …

Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.

JK Edwards, JB Bossaer, PO Lewis… - Journal of Oncology …, 2020 - search.ebscohost.com
Background: Peripheral neuropathy is a common treatment-related adverse effect
associated with vincristine. Vincristine is a major CYP3A4 substrate and is often …

Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.

JK Edwards, JB Bossaer, PO Lewis… - Journal of Oncology …, 2019 - europepmc.org
Background Peripheral neuropathy is a common treatment-related adverse effect associated
with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside …